Actinium Pharmaceuticals, Inc. 7AY1.F Stock
Actinium Pharmaceuticals, Inc. Price Chart
Actinium Pharmaceuticals, Inc. 7AY1.F Financial and Trading Overview
Actinium Pharmaceuticals, Inc. stock price | 8.94 EUR |
Previous Close | 7.25 EUR |
Open | 7 EUR |
Bid | 7 EUR x N/A |
Ask | 7.15 EUR x N/A |
Day's Range | 7 - 7 EUR |
52 Week Range | 4.49 - 19.8 EUR |
Volume | 1K EUR |
Avg. Volume | 232 EUR |
Market Cap | 184.87M EUR |
Beta (5Y Monthly) | 0.386619 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.57 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 32.5 EUR |
7AY1.F Valuation Measures
Enterprise Value | 113.93M EUR |
Trailing P/E | N/A |
Forward P/E | -7.5268817 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 2054.0957 |
Price/Book (mrq) | 3.148898 |
Enterprise Value/Revenue | 1265.94 |
Enterprise Value/EBITDA | -2.829 |
Trading Information
Actinium Pharmaceuticals, Inc. Stock Price History
Beta (5Y Monthly) | 0.386619 |
52-Week Change | 54.06% |
S&P500 52-Week Change | 20.43% |
52 Week High | 19.8 EUR |
52 Week Low | 4.49 EUR |
50-Day Moving Average | 7.98 EUR |
200-Day Moving Average | 9.1 EUR |
7AY1.F Share Statistics
Avg. Volume (3 month) | 232 EUR |
Avg. Daily Volume (10-Days) | 136 EUR |
Shares Outstanding | 26.41M |
Float | 25.7M |
Short Ratio | N/A |
% Held by Insiders | 2.25% |
% Held by Institutions | 22.21% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:30 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -45026.66% |
Gross Margin | 100.00% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -28.68% |
Return on Equity (ttm) | -61.76% |
Income Statement
Revenue (ttm) | 90K EUR |
Revenue Per Share (ttm) | 0.004 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | 1.03M EUR |
EBITDA | -40272000 EUR |
Net Income Avi to Common (ttm) | -38925000 EUR |
Diluted EPS (ttm) | -1.46 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 94.52M EUR |
Total Cash Per Share (mrq) | 3.58 EUR |
Total Debt (mrq) | 2.46M EUR |
Total Debt/Equity (mrq) | 4.3 EUR |
Current Ratio (mrq) | 12.531 |
Book Value Per Share (mrq) | 2.223 |
Cash Flow Statement
Operating Cash Flow (ttm) | -652000 EUR |
Levered Free Cash Flow (ttm) | -21811500 EUR |
Profile of Actinium Pharmaceuticals, Inc.
Country | Germany |
State | NY |
City | New York |
Address | 275 Madison Avenue |
ZIP | 10016 |
Phone | 646 677 3870 |
Website | https://www.actiniumpharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 49 |
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.
Q&A For Actinium Pharmaceuticals, Inc. Stock
What is a current 7AY1.F stock price?
Actinium Pharmaceuticals, Inc. 7AY1.F stock price today per share is 8.94 EUR.
How to purchase Actinium Pharmaceuticals, Inc. stock?
You can buy 7AY1.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Actinium Pharmaceuticals, Inc.?
The stock symbol or ticker of Actinium Pharmaceuticals, Inc. is 7AY1.F.
Which industry does the Actinium Pharmaceuticals, Inc. company belong to?
The Actinium Pharmaceuticals, Inc. industry is Biotechnology.
How many shares does Actinium Pharmaceuticals, Inc. have in circulation?
The max supply of Actinium Pharmaceuticals, Inc. shares is 30.04M.
What is Actinium Pharmaceuticals, Inc. Price to Earnings Ratio (PE Ratio)?
Actinium Pharmaceuticals, Inc. PE Ratio is now.
What was Actinium Pharmaceuticals, Inc. earnings per share over the trailing 12 months (TTM)?
Actinium Pharmaceuticals, Inc. EPS is -1.57 EUR over the trailing 12 months.
Which sector does the Actinium Pharmaceuticals, Inc. company belong to?
The Actinium Pharmaceuticals, Inc. sector is Healthcare.